REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Wolverine Stack

Recovery & Healingbeginner

92

synergy

92
Share
Peptides

2

Avg Daily mcg

3,000

Level

beginner

Added

May 17, 2026

Overview

The Wolverine Stack combines two of the most well-researched regenerative peptides in the biohacking community: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. It operates through multiple mechanisms including upregulation of growth factor receptors (VEGF, FGF, EGF), modulation of the nitric oxide system, and promotion of angiogenesis — the formation of new blood vessels at injury sites. In animal models, BPC-157 has demonstrated remarkable ability to accelerate healing of tendons, ligaments, muscles, and even bone. TB-500 is the active region of Thymosin Beta-4, a 43-amino-acid protein naturally present in nearly all human cells. It functions primarily by sequestering G-actin, which promotes cellular migration to wound sites, and by upregulating actin polymerization — essential for cellular repair and tissue remodeling. TB-500 also reduces inflammation by decreasing pro-inflammatory cytokines and promotes stem cell maturation and differentiation. The synergy between these two peptides is substantial. BPC-157 creates new vascular pathways to the injury site while TB-500 facilitates cellular migration along those pathways. BPC-157 provides local tissue-specific repair signaling while TB-500 offers systemic anti-inflammatory and repair activation. Together, they cover both the vascular supply and the cellular machinery needed for complete tissue regeneration. This combination is favored by athletes and individuals recovering from soft-tissue injuries, with many reporting noticeable improvement within 1-2 weeks of initiation.

Dosing Protocol

BPC-157

Twice per day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

TB-500

2x/week· subcutaneous

Read more about TB-500 →

2,500 mcg

per dose

Goals & Evidence

Injury recoveryTissue repairTendon healingMuscle recoveryJoint repair
Evidence tier:Animal Studies

Warnings

  • BPC-157 is FDA Category 2 — reclassification to Cat 1 expected by July 2026. TB-500 is also Category 2 pending reclassification.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.